Erratum: Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550) (J Infect Dis (2012) 205 (1705–8) DOI: 10.1093/infdis/jis269);Risk of tuberculosis reactivation with tofacitinib (CP-690550)

Journal of Infectious Diseases

Volumn 205, Issue 11, 2012, Pages 1705-1708

  Maiga, Mamoudou ^a   Lun, Shichun ^a   Guo, Haidan ^a   Winglee, Kathryn ^a   Ammerman, Nicole C ^a   Bishai, William R ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; JANUS KINASE INHIBITOR; TOFACITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; INFECTION RISK; INFLAMMATORY DISEASE; LATENT TUBERCULOSIS; LOW DRUG DOSE; MOUSE; NONHUMAN; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; TUBERCULOSIS;

EID: 84861043518     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/INFDIS/JIV311     Document Type: Erratum

References (15)

1. World Health Organization. Global tuberculosis control 2010. Geneva, Switzerland: World Health Organization Press, 2010.
2. Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol 2010; 185:15-22.
3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
4. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27:19-30. (Pubitemid 350212629)
5. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60:1895-905.
6. van Gurp E, Weimar W, Gaston R, et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 2008; 8:1711-8.
7. Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebocontrolled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 2009; 129:2299-302.
8. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2009; 180:1151-7.
9. Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 2004; 72:1065-71. (Pubitemid 38166689)
10. Krishnaswami S, Gupta P, French J, Cook J, Gruben D, Chan G. The effect of CP-690,550, a Janus kinase inhibitor, on QTC interval and blood pressure: a concentration-response analysis of phase I data. Transplantation 2008; 86:414.
11. Kudlacz E, Conklyn M, Andresen C, Whitney-Pickett C, Changelian P. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 2008; 582:154-61.
12. Medpage Today. http://www.medpagetoday.com/MeetingCoverage/EULAR/26693. Accessed 12 October 2011.
13. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186:4234-43.
14. Paige C, Bishai WR. Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell Microbiol 2010; 12:301-9.
15. Schuna AA, Megeff C. New drugs for the treatment of rheumatoid arthritis. Am J Health Syst Pharm 2000; 57:225-34.